Sponsor of the Day:
Jerkmate
https://medcitynews.com/2026/04/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra/
Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs - MedCity News
Apr 22, 2026 - Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences...
oral obesitymedcity newsupsizedipobrings
https://www.biospace.com/fda/eli-lillys-oral-obesity-pill-approved-kicking-off-renewed-novo-rivalry
Eli Lilly's Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry - BioSpace
Apr 2, 2026 - The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo...
eli lillyoral obesitypillapprovedkicking
https://www.biospace.com/press-releases/lexicon-pharmaceuticals-and-novo-nordisk-announce-initiation-of-phase-1-study-with-oral-obesity-drug-candidate-lx9851
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity...
novo nordiskphase 1oral obesitylexiconpharmaceuticals
https://pmc.ncbi.nlm.nih.gov/articles/PMC12498447/
From needles to pills: oral GLP-1 therapy enters the obesity arena - PMC
Obesity remains a major global health challenge, driving type 2 diabetes, cardiovascular disease, and other complications. Despite effective lifestyle and...
oral glp 1needlespillstherapyenters
https://www.biospace.com/business/despite-novos-robust-oral-wegovy-launch-access-remains-a-challenge-for-obesity-drugs
Despite Novo's Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs - BioSpace
Mar 25, 2026 - This year's catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk...
oral wegovyobesity drugsdespitenovorobust
https://www.biospace.com/fda/novos-wegovy-pill-wins-obesity-approval-securing-lead-in-oral-glp-1-race
Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race - BioSpace
Dec 23, 2025 - Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.
oral glp 1wegovy pillwinsobesityapproval
https://www.everydayhealth.com/weight-management/first-glp-1-pill-for-weight-loss-gets-fda-approval/
Wegovy Pill Wins FDA Approval as First GLP-1 Oral Treatment for Obesity and Weight Loss
Dec 23, 2025 - This new pill contains the same active ingredient as injectable Wegovy and Ozempic, semaglutide. It is the first GLP-1 pill approved for losing excess weight.
wins fda approvalwegovy pillglp 1oral treatmentweight loss
https://clinician.nejm.org/orforglipron-new-oral-option-treating-obesity-CLINdwNA60014
Orforglipron, a New Oral Option for Treating Obesity | NEJM Clinician
Read this Drug Watch article and more clinical summaries on NEJM Clinician.
new oralnejm clinicianorforglipronoptiontreating